Study Into the Effect of Pamidronate for the Prevention of Heterotopic Ossification in High-Risk Patients: A Randomized Controlled Trial

Not Applicable

Completed

• Conditions: Established heterotopic ossification; Musculoskeletal Diseases; Heterotopic ossification

• Registration Number: ISRCTN01332857
• Lead Sponsor: niversity Hospital of Basel (Switzerland)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-03-06
• Study Completion: 2008-06-01
• Last Update Posted: 4 March 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Consecutive patients with established HO (Brooker grade III-IV), hospitalized for resection of HO lesions

Exclusion Criteria

1. Age <20 years
2. Vitamin D deficiency (25OH vitamin D <30 ng/ml)
3. Renal insufficiency (clearance <50 ml/min)
4. Intolerance of bisphosphonates
5. Unable to provide informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary endpoint is the radiological HO recurrence rate

Secondary Outcome Measures

Name	Time	Method
Secondary endpoints are the clinical, functional and biochemical outcome (as assessed by several clinical and laboratory markers)